Table 2.

Phase 3 clinical trials that includes Immunotherapy for NSCLC in the first line.

	Pathology	PDL-1	Arm I (OS)	Arm II (OS)	HR
KEYNOTE-024	squamous (18%) and nonsquamous (82%)	≥50%	Pembrolizumab	Investigator’s choice of platinum-based chemotherapy
			30 months	14.2 months	0.63
KEYNOTE-042	squamous (38%) and nonsquamous (62%)	≥1%	Pembrolizumab	Investigator’s choice of platinum-based chemotherapy doublet
			16.7 months	12.1 months	0.81
KEYNOTE-189	nonsquamous	Any level	Pembrolizumab & Pemetrexed + Cisplatin/Carboplatin	Pemetrexed + Cisplatin/Carboplatin
			22 months	10.7 month	0.56
KEYNOTE-407	squamous	Any level	Pembrolizumab & Carboplatin + paclitaxel or nab–paclitaxel	Carboplatin + paclitaxel or nab–paclitaxel
			15.9 months	11.3 months	0.64
CHECKMATE-227	squamous (28%) and nonsquamous (72%)	Any level ≥1% <1%	Nivolumab and Ipilimumab	Cisplatin/Carboplatin + Gemcitabine (for squamous) or pemetrexed (nonsquamous)
			17.1 months	14.9 months	0.79
			17.2 months	12.2 months	0.62
CHECKMATE 9LA	squamous and nonsquamous	Any level	Nivolumab & Ipilimumab + Cisplatin/Carboplatin + Pemetrexed/Paclitaxel	Cisplatin/Carboplatin + Pemetrexed/Paclitaxel
			15.6 months	10.9 months	0.66
IMpower110	squamous (25%) and nonsquamous (75%)	≥50%	Atezolizumab	Cisplatin/Carboplatin + Gemcitabine (for squamous) or pemetrexed (nonsquamous)
			20.2 months	13.1 months	0.59
IMpower130	non-squamous	Any level	Atezolizumab & Carboplatin +nab-paclitaxel	Carboplatin +nab-paclitaxel
			18.6 months	13.9 months	0.79
IMpower150	non-squamous	Any level	Atezolizumab + Bevacizumab + Carboplatin, and Paclitaxel	Bevacizumab + Carboplatin, and Paclitaxel
			19.8 months	14.9 months	0.76